SCHEMBL3500182

SCHEMBL3500182

O=C(O)C=Cc1ccc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.55
MAPT P10636 7/20 0.55
KMT2A Q03164 6/20 0.55
HPGD P15428 5/20 0.55
MEN1 O00255 5/20 0.55
NPC1 O15118 5/20 0.55
LMNA P02545 4/20 0.55
RAB9A P51151 4/20 0.55
PKM P14618 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TP53 P04637 1/20 0.55
RARA P10276 1/20 0.54
KDM4E B2RXH2 6/20 0.53
HTT P42858 2/20 0.52
RECQL P46063 1/20 0.52
PRMT5 O14744 1/20 0.52
WDR77 Q9BQA1 1/20 0.52
GFER P55789 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3500178 1.00 ALDH1A1 (0.55) ALDH1A1MAPTKMT2AHPGDMEN1
Hydrochloric Acid SCHEMBL7055755 0.98 ALDH1A1 (0.54) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL6545574 0.87 ALDH1A1 (0.52) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL7055751 0.87 ALDH1A1 (0.52) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL2554807 0.85 ALDH1A1 (0.73) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL4350254 0.85 ALDH1A1 (0.73) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL5205567 0.84 MAPT (0.73) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL18169186 0.84 ALDH1A1 (0.64) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL18169185 0.84 ALDH1A1 (0.64) ALDH1A1MAPTKMT2AHPGDMEN1
SCHEMBL5205580 0.84 MAPT (0.73) ALDH1A1MAPTKMT2AHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4036981-A Method for treating inflammation MORTON-NORWICH PRODUCTS, INC. (US) 1977-07-19 US claimed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20080275153-A1 UV curable resin, its preparation and composition containing the same CHANG CHUN PLASTICS CO., LTD. (TW) 2008-11-06 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed
US-4036981-A Method for treating inflammation MORTON-NORWICH PRODUCTS, INC. (US) 1977-07-19 US disclosed
US-4036981-A Method for treating inflammation MORTON-NORWICH PRODUCTS, INC. (US) 1977-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 ALDH1A1 3047/4885MAPT 4820/4885KMT2A 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.